Investments
28Portfolio Exits
5About BayTech Venture Capital
BayTech Venture Capital is a European Venture Capital firm with the ambition to help the best entrepreneurs build the most successful companies in their fields of expertise. BayTech invests at an early stage in start-up companies in the sectors Technology and Life Sciences in Western Europe, especially in Germany and France.
Want to inform investors similar to BayTech Venture Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest BayTech Venture Capital News
Nov 26, 2014
November 26, 2014 0 Comments Munich-based life sciences company Pieris AG has raised 6.6 million euros in funding. The investors included Ally Bridge Group, OrbiMed, The Global Life Science Ventures, BioM Venture Capital, Gilde Europe Food & Agribusiness Fund and BayTech Venture Capital. Morrison & Foerster represented Ally Bridge Group in the transaction. PRESS RELEASE BERLIN/HONG KONG (November 26, 2014) – The international law firm Morrison & Foerster (MoFo) represented Ally Bridge Group in its first venture capital investment in Germany. The funding was provided for the fifth financing round of life sciences company Pieris AG, Munich, amounting to EUR 6.6 million in total. Other investors include premier life sciences venture capital investors OrbiMed, The Global Life Science Ventures, BioM Venture Capital, Gilde Europe Food & Agribusiness Fund, and BayTech Venture Capital. Ally Bridge Group (ABG) is a global healthcare-focused investment group, based in Hong Kong and the United States. ABG and its affiliates manage over USD 500 million in assets in the United States, China and Europe with a focus on disruptive technology platforms in both biopharmaceuticals and medical devices. The MoFo corporate team was led by Hong Kong partner Thomas Chou, Berlin partner Dirk Besse and senior associate Robin Eyben. Berlin counsel Sebastian Kost and Hong Kong associate Matthew Lau provided assistance on tax aspects of the deal. Pieris AG is a clinical-stage biotechnology stock corporation based in Munich, Germany, that exploits its propriatory Anticalin technology developing differentiated drugs to help patients suffering from cancer, severe asthma, anemia and other medical conditions. ABOUT MORRISON & FOERSTER We are Morrison & Foerster — a global firm of exceptional credentials. Our clients include some of the largest financial institutions, investment banks, and Fortune 100, technology, and life sciences companies. We’ve been included on The American Lawyer’s A-List for 11 straight years, and the Financial Times named the firm number six on its 2013 list of the 40 most innovative firms in the United States. Our lawyers are committed to achieving innovative and business-minded results for our clients, while preserving the differences that make us stronger. Leave a Reply
BayTech Venture Capital Investments
28 Investments
BayTech Venture Capital has made 28 investments. Their latest investment was in PandoLogic as part of their Series B on November 11, 2010.
BayTech Venture Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/16/2010 | Series B | PandoLogic | $4.7M | No | 1 | |
12/11/2009 | Series D | EnOcean | $12M | No | 1 | |
8/20/2009 | Series B - II | Ubidyne | $14.4M | No | 1 | |
7/11/2009 | Series C | |||||
12/19/2008 | Series A |
Date | 11/16/2010 | 12/11/2009 | 8/20/2009 | 7/11/2009 | 12/19/2008 |
|---|---|---|---|---|---|
Round | Series B | Series D | Series B - II | Series C | Series A |
Company | PandoLogic | EnOcean | Ubidyne | ||
Amount | $4.7M | $12M | $14.4M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 1 | 1 | 1 |
BayTech Venture Capital Portfolio Exits
5 Portfolio Exits
BayTech Venture Capital has 5 portfolio exits. Their latest portfolio exit was PandoLogic on July 22, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/22/2021 | Acquired | 5 | |||
Date | 7/22/2021 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 5 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
